Loading company…
OccamzRazor uses machine learning to support drug discovery for Parkinson's and other complex diseases.
Founded in 2015, OccamzRazor develops machine-learning methods to identify disease targets and mechanisms, with a focus on brain aging and Parkinson's disease. Its platform draws on research publications, datasets, clinical trials, and laboratory experiments. Based in New York, the company raised USD 6.1 million in March 2022 from an individual investor, Lauder Partners, re. Mind Capital, and Valor Equity Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in